EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

SP-CHAP, an endolysin with enhanced activity against biofilm pneumococci and nasopharyngeal colonization

Adit B Alreja iD, Amanda E Appel, Jinyi C Zhu, Sean P Riley iD, Norberto Gonzalez-Juarbe iD, Daniel C Nelson iD

mBio · 2024

DOI: 10.1128/mbio.00069-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mBio, 2024. Verfasst von Adit B Alreja und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, Maryland, USA. Hauptthemen laut MEDLINE: Pneumococcal Infections, Bacteriophages. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, HHS | NIH | National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Streptococcus pneumoniae ( Spn ), a Gram-positive bacterium, is responsible for causing a wide variety of invasive infections. The emergence of multi-drug antibiotic resistance has prompted the search for antimicrobial alternatives. Phage-derived peptidoglycan hydrolases, known as endolysins, are an attractive alternative. In this study, an endolysin active against Spn , designated SP-CHAP, was cloned, produced, purified, biochemically characterized, and evaluated for its antimicrobial properties. Cysteine, histidine-dependent amidohydrolase/peptidase (CHAP) domains are widely represented in bacteriophage endolysins but have never previously been reported for pneumococcal endolysins. Here, we characterize the first pneumococcal endolysin with a CHAP catalytic domain. SP-CHAP was antimicrobial against all Spn serovars tested, including capsular and capsule-free pneumococci, and it was found to be more active than the most widely studied pneumococcal endolysin, Cpl-1, while not affecting various oral or nasal commensal organisms tested. SP-CHAP was also effective in eradicating Spn biofilms at concentrations as low as 1.56 µg/mL. In addition, a Spn mouse nasopharyngeal colonization model was employed, which showed that SP-CHAP caused a significant reduction in Spn colony-forming units, even more than Cpl-1. These results indicate that SP-CHAP may represent a promising alternative to combating Spn infections. IMPORTANCE Considering the high rates of pneumococcal resistance reported for several antibiotics, alternatives are urgently needed. In the present study, we report a Streptococcus pneumoniae -targeting endolysin with even greater activity than Cpl-1, the most characterized pneumococcal endolysin to date. We have employed a combination of biochemical and microbiological assays to assess the stability and lytic potential of SP-CHAP and demonstrate its efficacy on pneumococcal biofilms in vitro and in an in vivo mouse model of colonization. Our findings highlight the therapeutic potential of SP-CHAP as an antibiotic alternative to treat Streptococcus pneumoniae infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pneumococcal InfectionsBacteriophagesAnimalsMicePeptide HydrolasesStreptococcus pneumoniaeCysteineHistidineAmidohydrolasesEndopeptidasesAnti-Bacterial AgentsBiofilms

Stichwörter der Autor:innen

CHAP domainantibiotic resistancebacteriophageendolysinpneumococcus

Substanzen

endolysinPeptide HydrolasesCysteineHistidineAmidohydrolasesEndopeptidasesAnti-Bacterial Agents

Autor:innen und Institutionen

  • Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, Maryland, USA.
  • Department of Infectious Diseases and Genomic Medicine, J. Craig Venter Institute, Rockville, Maryland, USA.
  • Department of Veterinary Medicine, University of Maryland, College Park, Maryland, USA.
  • Department of Cell Biology and Molecular Genetics, University of Maryland, College Park, Maryland, USA.

ORCID-Profile: Adit B Alreja, Sean P Riley, Norberto Gonzalez-Juarbe, Daniel C Nelson

Förderung

  • NIAID NIH HHS
  • HHS | NIH | National Institute of Allergy and Infectious Diseases

Zitieren

APA

Alreja, A. B., Appel, A. E., Zhu, J. C., Riley, S. P., Gonzalez-Juarbe, N., & Nelson, D. C. (2024). SP-CHAP, an endolysin with enhanced activity against biofilm pneumococci and nasopharyngeal colonization. mBio. https://doi.org/10.1128/mbio.00069-24

Vancouver

Alreja AB, Appel AE, Zhu JC, Riley SP, Gonzalez-Juarbe N, Nelson DC. SP-CHAP, an endolysin with enhanced activity against biofilm pneumococci and nasopharyngeal colonization. mBio. 2024. doi:10.1128/mbio.00069-24

BibTeX
@article{Alreja2024,
  author = {Alreja, Adit B and Appel, Amanda E and Zhu, Jinyi C and Riley, Sean P and Gonzalez-Juarbe, Norberto and Nelson, Daniel C},
  title = {SP-CHAP, an endolysin with enhanced activity against biofilm pneumococci and nasopharyngeal colonization},
  journal = {mBio},
  year = {2024},
  doi = {10.1128/mbio.00069-24}
}
Kostenlos starten →